Evidence map›Paper›PMID 23225217›Full record

ArticleEuropean journal of immunology2013

Recirculating bone marrow B cells in C57BL/6 mice are more tolerant of highly hydrophobic and highly charged CDR-H3s than those in BALB/c mice.

Mohamed Khass, Kevin Buckley, Pratibha Kapoor, Robert L Schelonka, Leticia S Watkins, Yingxin Zhuang, Harry W Schroeder

Open access · bronzeAbstract read
In one paragraph

Article in European journal of immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mohamed KhassDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Kevin Buckley
Pratibha Kapoor
Robert L Schelonka
Leticia S Watkins
Yingxin Zhuang
Harry W Schroeder
University of Alabama at Birmingham · USOregon Health & Science University · USWake Forest University · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
IMMUNOLOGIC DISEASES AND BASIC IMMUNOLOGYT32AI007051 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laurie Ellen Harrington · 1985 to 2026
$13.1M
ROS Modulation of Innate and Adaptive Immunity in RAP30AR048311 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOUNTZ, JOHN D · 2001 to 2017
$9.5M
The role of Immunoglobulin CDRH3 in Autoimmune DiseaseR01AI048115 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCHROEDER, HARRY WILLIAM · 2000 to 2010
$3.1M
DEVELOPMENT OF THE ANTIBODY REPERTOIRER01AI047322 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCHROEDER, HARRY WILLIAM · 2001 to 2005
$1.5M
Role of IG CDR-H3 in Responses to HIV VaccinesR01AI090742 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCHROEDER, HARRY WILLIAM · 2010 to 2013
$1.5M
Role of CDR3 in the Development of Neonatal ImmunityK08HD043327 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCHELONKA, ROBERT LEWIS · 2003 to 2007
$582k
Developing and Improving Institutional Animal ResourcesG20RR025858 · NCRR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CARTNER, SAMUEL CORBIN · 2009 to 2009
$499k
Role of immunoglobulin CDR-H3 in heterosubtypic immunity to influenza virusR21AI088498 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCHROEDER, HARRY WILLIAM · 2010 to 2011
$401k
The Role of Immunoglobulin CDRH3 in Autoimmune DiseaseR56AI048115 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCHROEDER, HARRY WILLIAM · 2012 to 2012
$366k
NCI NIH HHS P30 CA013148NCI NIH HHS P30 CA13148NCRR NIH HHS G20 RR025858NCRR NIH HHS G20RR025858NIAID NIH HHS AI42732NIAID NIH HHS AI48115NIAID NIH HHS P30 AI027767NIAID NIH HHS P30AI027767NIAID NIH HHS R01 AI047322NIAID NIH HHS R01 AI048115NIAID NIH HHS R01 AI090742NIAID NIH HHS R21 AI088498NIAID NIH HHS R56 AI048115NIAID NIH HHS T32 AI007051NIAMS NIH HHS P30 AR048311NIAMS NIH HHS P30 AR48311NICHD NIH HHS HD043327NICHD NIH HHS K08 HD043327
6 · The paper itself

Abstract

To test whether mechanisms controlling the range of diversity of the developing antibody repertoire in C57BL/6 mice (IgH(b)) operate similarly to those identified in BALB/c mice (IgH(a)), we compared the sequences of VH 7183-containing H-chain transcripts from sorted adult bone marrow C57BL/6 B-cell subsets with those previously obtained from BALB/c mice. Patterns of VDJ gene segment utilization and CDR-H3 amino acid composition, charge, and average length in C57BL/6 pro-B cells were similar, although not identical, to BALB/c pro-B cells. However, C57BL/6 mature, recirculating B cells failed to demonstrate the reduction in the use of VH81X and the narrowing in the range of variance of CDR-H3 hydrophobicity that characterizes B-cell maturation in BALB/c mice. To further test the ability of the C57BL/6 strain to discard B cells expressing highly charged CDR-H3s, we introduced a mutant IgH(a) DH allele that forces use of arginine, asparagine, and histidine. Unlike BALB/c mice, C57BL/6 mice congenic for the charged DH maintained normal numbers of mature, recirculating B cells that were enriched for charged CDR-H3s. Together these findings indicate that the mature C57BL/6 B-cell pool permits expression of immunoglobulins with antigen-binding sites that are typically discarded during late-stage bone marrow B-cell development in BALB/c mice.

Indexed as

AnimalsAntibody DiversityB-LymphocytesB-Lymphocyte SubsetsBone Marrow CellsCell DifferentiationCodonComplementarity Determining RegionsFemaleGene Rearrangement, B-Lymphocyte, Heavy ChainHydrophobic and Hydrophilic InteractionsImmunoglobulin Heavy ChainsMiceMice, Inbred BALB CMice, Inbred C57BLReading FramesCodonComplementarity Determining RegionsImmunoglobulin Heavy Chains

Identifiers

PMID23225217
PMCPMC3653428
OpenAlexW1524550388

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.